Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack II - A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: SpecialK who wrote (41492)	12/12/2002 10:39:45 AM
From: SpecialK	Read Replies (1) \| Respond to of 52237

Amgen guides FY02 and FY03 above consensus (AMGN) 47.27: For 2002, co sees EPS of $1.37-$1.39 (consensus $1.36). Co provides 2003 guidance of $1.70-$1.80, which is above the Multex consensus of $1.65. Puts total 2003 revs at $7.3-$7.8 bln (consensus $7.25 bln). Amgen indicated that, to date, Wyeth has sold approx. 55 mln of the 98 mln AMGN shares company received from the Immunex acquisition. If Wyeth has been selling all these shares, this has been and may continue to be a weight on AMGN shares. Sooner or later, that will be gone, then AMGN will rise.